HeartFlow delivers AI-powered, non-invasive cardiac diagnostics for hospitals and cardiology clinics using proprietary ...
HealthDay on MSNOpinion
Fatty liver disease tied to higher risk for major adverse cardiovascular events
Hepatic steatosis is associated with greater noncalcified plaque burden (NCPB) and an increased risk for a major adverse ...
Tribune Online on MSN
White House releases Trump’s annual health report
The White House has released the results of United States President Donald Trump’s latest annual physical examination, saying the 79-year-old remains in good health and fit to carry out the duties of ...
A late-night medical report released by the White House on Friday declares President Donald Trump to be in “excellent health” and fully fit for office, pushing back against recent cable news ...
Mediaite on MSN
Trump Doctor’s Report Drops Late Friday Night — Details 238-Pound 6 ft 3 President’s Health, Cognitive Results
A few minutes before 11 PM on Friday night, Dr. Sean Barbarella's memo on President Donald Trump's physical exam was released by the White House. The post Trump Doctor’s Report Drops Late Friday Night ...
6don MSN
Cardiologist explains why having a calcium score of zero does not make a person ‘heart attack proof’
Calcium score is a risk assessment tool and not a diagnostic test, as such, it cannot guarantee no chance of heart attack, explains Dr Yaranov.
The Healthy @Reader's Digest on MSN
Study: This Common Liver Disease Nearly Doubles the Risk of Heart Attack
It's "not only a liver condition but also an important marker of heart disease risk,” says one of the study's authors.
President Donald Trump is in "excellent health" and is "fully fit to carry out all duties of the Commander-in-Chief and Head of State," his doctor said.
Aortic aneurysms are among the most dangerous vascular conditions affecting the human body. The aorta, which is the largest ...
MarketBeat on MSN
Heartflow Q1 Earnings Call Highlights
Heartflow (NASDAQ:HTFL) reported a sharply higher first-quarter revenue total and raised its full-year 2026 outlook, citing strength in its core FFRCT business, faster-than-expected adoption of its ...
A clinical trial of more than 3,600 patients evaluated for chest pain showed that fatty liver disease was linked to nearly ...
A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results